Paul Thomen

Friday, 14 June 2013

Generic and innovative drugs market in Central Europe 2013

Compare generic & innovative drug markets across Central Europe.

Report studies reimbursement regulations; forecasts market growth for 2013-2015.
Generic and innovative medicines represent key advancements in the regional pharmaceutical industry of Central Europe. The markets for these preparations have become especially complex due to varying conditions that exist in each individual country. For example, generics represent a larger share of the market in Poland than in Romania, Slovakia, the Czech Republic, Hungary or Bulgaria. In addition, innovative drug segments have experienced different growth rates across borders, and regulatory and reimbursement policies vary from country to country and are subject to change with the passage of each new legislative measure.

Now there is a convenient way to stay updated on changes and understand developments in these high-potential markets. Readers recommend Generic and innovative drugs market in Central Europe 2013, Comparative analysis, reimbursement policies and development forecasts for 2013-2015.

This comprehensive report from PMR includes statistics on value and volume of the overall regional CE market and zeroes in on the specifics of the generic and innovative drug segments in each of six Central European countries: Poland, Romania, Slovakia, the Czech Republic, Hungary and Bulgaria. It supplies market share of each segment within the overall pharmaceutical sector of each country, along with detailed forecasts for growth and expansion in 2013-2015.

Readers will learn about drug pricing variations in each country, from VAT rates and allowable mark-ups to government regulations governing drug prices in connection to reimbursement list status. The report examines entire reimbursement systems in each country in terms of listing, modifications and procedures and policies in each specific country, along with changes expected to occur in the years ahead. It also features coverage of patent expiry periods and data exclusivity periods in each country, with lists of SPCs (Supplementary Protection Certificates) currently issued in each of the six highlighted countries.

This publication also provides detailed coverage of additional topics including the market shares of counterfeit products in each country, the specific procedures used to deal with these products, attitudes of patients and medical professionals toward the use of generic and innovative preparations and best selling generic and innovative drugs in the CE market and in each country.

Viewed by many users as seven reports in one, Generic and innovative drugs market in Central Europe 2013, Comparative analysis, reimbursement policies and development forecasts for 2013-2015 is a powerful tool for professionals who wish to perform comparative analysis of conditions in these important market segments as they exist in each country within the region. It is also an affordable and worthwhile compendium of essential guidance for those seeking updates on reimbursement lists and policies in these six countries, creating a new business strategy or preparing a winning product portfolio.

Manufacturers, distributors, trade groups, consultants, financial services specialists and academic and research concerns represent just a few of the organisations occupied by professionals who will benefit from access to this unique and timely business intelligence resource.

Table of Content

I. Methodology 15
II. Executive summary 21
III. Characteristics of generic and innovative drug markets in Central European countries 31
IV. Bestselling drugs in Central Europe 93
V. Counterfeit products 117
VI. Reimbursement and pricing policies in Central Europe 123
VII. Key manufacturers 213
VIII. List Of Graphs 289
IX. List Of Tables 295
X. About PMR 301

For more details contact Mr. Priyank Tiwari: / +18883915441

No comments:

Post a Comment

Note: only a member of this blog may post a comment.